M E Lacouture

Summary

Affiliation: Northwestern University
Country: USA

Publications

  1. ncbi Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective
    M E Lacouture
    SERIES Clinic, Department of Dermatology and Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
    Skin Therapy Lett 12:1-5. 2007
  2. ncbi Clinical management of EGFRI dermatologic toxicities: US perspective
    Mario E Lacouture
    Department of Dermatology, Comprehensive Cancer Center, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA
    Oncology (Williston Park) 21:17-21. 2007
  3. doi Analysis of dermatologic events in patients with cancer treated with lapatinib
    M E Lacouture
    Department of Dermatology, Northwestern University, 676 North St Claire Street, Suite 1600, Chicago, IL 60611 2941, USA
    Breast Cancer Res Treat 114:485-93. 2009
  4. ncbi The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors
    Mario E Lacouture
    Department of Dermatology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois 60611, USA
    J Support Oncol 4:236-8. 2006
  5. ncbi Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor
    M E Lacouture
    Section of Dermatology, Department of Medicine, University of Chicago, IL, USA
    Clin Exp Dermatol 31:783-5. 2006
  6. ncbi Mechanisms of cutaneous toxicities to EGFR inhibitors
    Mario E Lacouture
    SERIES Clinic and Cancer Skin Care Program, Department of Dermatology, Northwestern University Feinberg School of Medicine, 676 North Saint Clair Suite 1600, Chicago, Illinois 60611, USA
    Nat Rev Cancer 6:803-12. 2006
  7. doi Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib
    M E Lacouture
    Department of Dermatology, SERIES Clinic, Northwestern University s Feinberg School of Medicine, Chicago, IL 60611, USA
    Ann Oncol 19:1955-61. 2008
  8. doi Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib
    Mario E Lacouture
    Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Oncologist 13:1001-11. 2008
  9. doi Higher severity grade of erlotinib-induced rash is associated with lower skin phototype
    M Luu
    Northwestern University Feinberg School of Medicine, Chicago, IL, USA
    Clin Exp Dermatol 36:733-8. 2011
  10. pmc A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension
    M Gomberg-Maitland
    Section of Cardiology, Department of Medicine, University of Chicago, Chicago, Illinois, USA
    Clin Pharmacol Ther 87:303-10. 2010

Collaborators

Detail Information

Publications28

  1. ncbi Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective
    M E Lacouture
    SERIES Clinic, Department of Dermatology and Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
    Skin Therapy Lett 12:1-5. 2007
    ....
  2. ncbi Clinical management of EGFRI dermatologic toxicities: US perspective
    Mario E Lacouture
    Department of Dermatology, Comprehensive Cancer Center, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA
    Oncology (Williston Park) 21:17-21. 2007
    ..Two dermatologists who treat high numbers of patients affected by these EGFRI-induced cutaneous side effects submit their recommendations for management...
  3. doi Analysis of dermatologic events in patients with cancer treated with lapatinib
    M E Lacouture
    Department of Dermatology, Northwestern University, 676 North St Claire Street, Suite 1600, Chicago, IL 60611 2941, USA
    Breast Cancer Res Treat 114:485-93. 2009
    ..Dermatologic events (DEs) in patients with cancer treated with lapatinib, a small-molecule dual tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR [ErbB1]) and HER2 (ErbB2), were characterized...
  4. ncbi The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors
    Mario E Lacouture
    Department of Dermatology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois 60611, USA
    J Support Oncol 4:236-8. 2006
  5. ncbi Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor
    M E Lacouture
    Section of Dermatology, Department of Medicine, University of Chicago, IL, USA
    Clin Exp Dermatol 31:783-5. 2006
    ..This side-effect is of clinical importance, as early recognition is critical for early treatment and may represent a source of additional morbidity to these patients...
  6. ncbi Mechanisms of cutaneous toxicities to EGFR inhibitors
    Mario E Lacouture
    SERIES Clinic and Cancer Skin Care Program, Department of Dermatology, Northwestern University Feinberg School of Medicine, 676 North Saint Clair Suite 1600, Chicago, Illinois 60611, USA
    Nat Rev Cancer 6:803-12. 2006
    ..There is an urgent need for an improved understanding of these toxicities to develop adequate staging systems and mechanistically driven therapies, and to ensure quality of life and consistent antineoplastic therapy...
  7. doi Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib
    M E Lacouture
    Department of Dermatology, SERIES Clinic, Northwestern University s Feinberg School of Medicine, Chicago, IL 60611, USA
    Ann Oncol 19:1955-61. 2008
    ..This study examined clinicopathological findings and management of hand foot skin reaction (HFSR) to sorafenib and sunitinib in a dermatology referral center for cancer-related toxic effects...
  8. doi Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib
    Mario E Lacouture
    Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Oncologist 13:1001-11. 2008
    ..Based on these proceedings, recommendations for the management of HFSR have been provided to offer patients the best possible quality of life while taking these drugs and to optimize the patient benefit associated with MKI therapy...
  9. doi Higher severity grade of erlotinib-induced rash is associated with lower skin phototype
    M Luu
    Northwestern University Feinberg School of Medicine, Chicago, IL, USA
    Clin Exp Dermatol 36:733-8. 2011
    ..Because the level of the biological pigment melanin correlates with increased protection against UVR, we hypothesized that lighter levels of skin pigmentation are associated with greater severity of rash...
  10. pmc A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension
    M Gomberg-Maitland
    Section of Cardiology, Department of Medicine, University of Chicago, Chicago, Illinois, USA
    Clin Pharmacol Ther 87:303-10. 2010
    ..The most common adverse events were moderate skin reactions on the hands and feet and alopecia. Our conclusion was therefore that this is a tolerable dosing regimen for testing the therapeutic activity of sorafenib in PAH patients...
  11. doi Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib
    S E Rosenbaum
    Department of Dermatology, Northwestern University, Feinberg School of Medicine, 676 N St Clair St, Suite 1600, Chicago, IL 60611, USA
    Support Care Cancer 16:557-66. 2008
    ..However, sunitinib is frequently associated with dermatological adverse reactions. The physical and psychosocial impact of frequent dermatological toxicities can affect consistent antineoplastic therapy and quality of life...
  12. doi The effect of cytotoxic chemotherapy on the risk of high-grade acneiform rash to cetuximab in cancer patients: a meta-analysis
    Y Balagula
    Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 160 East 53rd Street, New York, NY 10022, USA
    Ann Oncol 22:2366-74. 2011
    ..We carried out a systematic review and meta-analysis of published studies to quantify the incidence and risk of high-grade acneiform rash with combination therapy...
  13. ncbi Treatment of radiation-relapsing primary cutaneous B-cell lymphoma with an anti-CD20 monoclonal antibody
    M E Lacouture
    Section of Dermatology, Department of Medicine, University of Chicago Pritzker School of Medicine, Chicago, IL, USA
    Clin Exp Dermatol 30:46-8. 2005
    ..These are two of the few cases in the literature showing that rituximab is an effective and well-tolerated treatment for radiotherapy-relapsing primary cutaneous B cell lymphoma...
  14. doi An interdisciplinary consensus on managing skin reactions associated with human epidermal growth factor receptor inhibitors
    Beth Eaby
    University of Pennsylvania, Philadelphia, PA, USA
    Clin J Oncol Nurs 12:283-90. 2008
    ..The result was a proposal for a simple, three-tiered grading system for skin toxicities related to HER1/EGFR inhibitors to be used in therapeutic decision making and as a framework for building a stepwise approach to intervention...
  15. doi Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts
    Roger von Moos
    Medical Oncology, Kantonsspital Graubunden, Loestrasse 170, Chur 7000, Switzerland
    Eur J Cancer 44:781-90. 2008
    ..It can cause considerable discomfort and lead to therapy interruption. Numerous approaches to HFS management have been reported, but there is no consensus...
  16. doi Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis
    David Chu
    Division of Medical Oncology, Department of Medicine, State University of New York at Stony Brook, Stony Brook, NY 11794, USA
    Acta Oncol 47:176-86. 2008
    ..This study was conducted to determine the risk of developing HFSR among patients receiving sorafenib...
  17. ncbi Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results
    Susan L Boone
    Department of Dermatology, SERIES Clinic, Northwestern University s Feinberg School of Medicine, Chicago, Ill 60611, USA
    Oncology 72:152-9. 2007
    ..The survey results support that attentive cutaneous care is important in patients treated with EGFR inhibitors, and that proactive/combined interventions may enhance quality of life and optimize consistent drug administration...
  18. ncbi Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae
    Lynne I Wagner
    Center on Outcomes, Research and Education, Evanston Northwestern Healthcare, Northwestern University, Feinberg Medical School, Chicago, IL 60611, USA
    Oncology (Williston Park) 21:34-6. 2007
    ..Cognitive behavioral strategies may also be useful in helping patients manage anxiety and depression associated with any changes in their social function caused by skin rash, as well as distress associated with having a cancer diagnosis...
  19. ncbi Hand-foot and stump syndrome to sorafenib
    Susan E Lai
    Department of Dermatology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
    J Clin Oncol 25:341-3. 2007
  20. ncbi Non-rash skin toxicities associated with novel targeted therapies
    Mario E Lacouture
    Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL 48201, USA
    Clin Lung Cancer 8:S36-42. 2006
    ..This review discusses several non-rash dermatologic toxicities observed with targeted therapeutic agents and guidelines for their diagnosis and treatment...
  21. ncbi Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinib
    Minnelly Luu
    Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA
    Photodermatol Photoimmunol Photomed 23:42-5. 2007
    ....
  22. ncbi Temporal dependence of the effect of radiation on erlotinib-induced skin rash
    Mario E Lacouture
    J Clin Oncol 25:2140; author reply 2141. 2007
  23. ncbi Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management
    Thomas J Lynch
    Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Oncologist 12:610-21. 2007
    ..The goal is to maximize quality of life in patients who are being treated with these agents--many of whom will be on these drugs for several months or even years...
  24. ncbi Insights into the pathophysiology and management of dermatologic toxicities to EGFR-targeted therapies in colorectal cancer
    Mario E Lacouture
    Cancer Skin Care Program and SERIES Clinic, Department of Dermatology, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Ill 60611 2941, USA
    Cancer Nurs 30:S17-26. 2007
    ..Effective management of these adverse effects may lessen the chance of suboptimal therapy and requires an understanding of the underlying pathophysiology, as well as knowledge of useful strategies for alleviating these effects...
  25. ncbi Dermatologic challenges in cancer patients and survivors
    Rania Agha
    Department of Dermatology, Indiana University School of Medicine, Indianapolis, Indiana, USA
    Oncology (Williston Park) 21:1462-72; discussion 1473, 1476, 1481 passim. 2007
    ..This review provides a basis for the understanding of dermatologic events in the oncology setting, in order to promote attentive care to cutaneous health in cancer patients and survivors...
  26. ncbi Clinical presentation and pathophysiology of EGFRI dermatologic toxicities
    Edith P Mitchell
    Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
    Oncology (Williston Park) 21:4-9. 2007
    ..Most management strategies for these toxicities have been based on anecdotal experience; clinical trials are needed to provide uniform characterization to allow for evidence-based treatment strategies...
  27. ncbi The promise of molecular targeted therapies: protein kinase inhibitors in the treatment of cutaneous malignancies
    Lavanya Kondapalli
    Pritzker School of Medicine, The University of Chicago, Chicago, Illinois, USA
    J Am Acad Dermatol 53:291-302. 2005
    ..These drugs will have important implications in clinical dermatology, based on their expected frequent use in the treatment of dermatologic malignancies, and their associated cutaneous side effects...
  28. ncbi Skin rash in a transplant patient receiving multiple drugs
    Mario E Lacouture
    Section of Dermatology, University of Chicago Hospitals, USA
    Cleve Clin J Med 70:1071-5. 2003